Day

June 24, 2023
24
Jun

Robust PSA Drops With Radionuclide Therapy in Castration-Resistant Prostate Cancer

An investigational radionuclide therapy targeting prostate-specific membrane antigen (PSMA) achieved biochemical responses in 70% of patients with castration-resistant prostate cancer (CRPC), and prostate-specific antigen (PSA) reductions in all but one patient, enrolled in a small preliminary clinical trial.

Read More

About Us

GCG Global Healthcare are specialists in healthcare excellence. Driven by a desire to improve healthcare and clinical solutions for everyone – patients, medical professionals and facilities. Gloreen G at GCG has vast experience and understanding of the specialist medical and diagnostic imaging market. This gives GCG the ability to ensure that you receive the very best salary and incentives package, including leave entitlements, days off, paid conferences and radiology expenses.